Breast carcinoma in situ: An observational study of tumor subtype, treatment and outcomes

Background & Aims To evaluate the clinical presentation, treatment and outcome of patients with breast carcinoma in situ (BCIS) with special emphasis on the role of the tumor subtype and local treatment in these patients. Methods Using data obtained by the Surveillance, Epidemiology, and End Results (SEER) program from 2010-2013, a retrospective, population-based cohort study was conducted to investigate tumor subtype-specific differences in various characteristics, overall survival (OS) and breast cancer-specific mortality (BCSM). Results In all, 6867 patients with BCIS were eligible during the 2010-2013 study period. Compared with the hormone receptor (HoR)+/HER- subgroup, patients with triple negative (TN) breast cancer were more likely to have tumors that were higher in grade and larger in size; they were also more likely to have tumors with ductal and comedo histology and were less likely to have tumors with cribriform and papillary histology (each P < 0.05). During the follow-up period, patients with TN breast cancer had an OS of 97.0% compared with 98.6 % in the HoR+/HER- subgroup (P < 0.05). Furthermore, the BCSM rate was 1.0% for the TN group compared with 0.1% for the HoR+/HER- subgroup (P < 0.05). Multivariate analysis revealed that patients with TN MBC had a poorer OS and BCSM (P <0.05). Multivariate analysis of OS with respect to the local treatment history showed that patients who received breast-conserving surgery (BCS) combined with radiotherapy (R) were more likely to have an improved OS (P < 0.05). Moreover, the results demonstrated that patients who underwent SLNB were more likely to have a lower BCSM (P < 0.05). Conclusions The results demonstrate that BCIS appears to alter the prognosis associated with the TN subtype. Meanwhile, BCS plus R was a preferable option and resulted in survival rates that were better than those achieved with mastectomy; thus, SLNB should be considered as an appropriate assessment of axillary staging in patients with BCIS.

[1]  F. Vicini,et al.  Management of Ductal Carcinoma In Situ of the Breast: A Review. , 2016, JAMA oncology.

[2]  E. Karavaş,et al.  Male Mondor's Disease is a Rare Entity , 2016, The breast journal.

[3]  T. Kühn,et al.  Updates in the treatment of ductal carcinoma in situ of the breast , 2015, Current opinion in obstetrics & gynecology.

[4]  A. Jemal,et al.  Cancer statistics: Breast cancer in situ , 2015, CA: a cancer journal for clinicians.

[5]  K. Hunt,et al.  Outcomes of Sentinel Lymph Node Dissection Alone vs. Axillary Lymph Node Dissection in Early Stage Invasive Lobular Carcinoma: A Retrospective Study of the Surveillance, Epidemiology and End Results (SEER) Database , 2014, PloS one.

[6]  T. Sørlie,et al.  Molecular subtypes in ductal carcinoma in situ of the breast and their relation to prognosis: a population-based cohort study , 2013, BMC Cancer.

[7]  S. Kurbel.  In search of triple-negative DCIS: tumor-type dependent model of breast cancer progression from DCIS to the invasive cancer , 2013, Tumor Biology.

[8]  F. Kasumi,et al.  Significance of HER2 protein examination in ductal carcinoma in situ. , 2011, The Journal of surgical research.

[9]  P. V. van Diest,et al.  Molecular differences between ductal carcinoma in situ and adjacent invasive breast carcinoma: a multiplex ligation-dependent probe amplification study , 2011, Cellular Oncology.

[10]  S. Duffy,et al.  Molecular subtyping of DCIS: heterogeneity of breast cancer reflected in pre-invasive disease , 2010, British Journal of Cancer.

[11]  T. Julian,et al.  Sentinel lymph node biopsy and management of the axilla in ductal carcinoma in situ. , 2010, Journal of the National Cancer Institute. Monographs.

[12]  G. van Tienhoven,et al.  Local and systemic outcomes in DCIS based on tumor and patient characteristics: the radiation oncologist's perspective. , 2010, Journal of the National Cancer Institute. Monographs.

[13]  Karla Kerlikowske,et al.  Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis. , 2010, Journal of the National Cancer Institute.

[14]  R. Kane,et al.  Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes. , 2010, Journal of the National Cancer Institute.

[15]  H. Nisenbaum,et al.  HER-2/neu Overexpression as a Predictor for the Transition from In situ to Invasive Breast Cancer , 2009, Cancer Epidemiology Biomarkers & Prevention.

[16]  Robert D Cardiff,et al.  Ductal carcinoma in situ: state of the science and roadmap to advance the field. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  J. Darcourt,et al.  The sentinel lymph node procedure for patients with preoperative diagnosis of ductal carcinoma in situ: risk factors for unsuspected invasive disease and for metastatic sentinel lymph nodes , 2008, International journal of clinical practice.

[18]  M. Ernst,et al.  The value of sentinel lymph node biopsy in ductal carcinoma in situ (DCIS) and DCIS with microinvasion of the breast. , 2008, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[19]  H. Kuerer,et al.  The molecular journey from ductal carcinoma in situ to invasive breast cancer , 2008, Cancer.

[20]  M. Antoine,et al.  Ductal carcinoma in situ: Value of sentinel lymph node biopsy , 2006, Journal of surgical oncology.

[21]  C. Magnant,et al.  Sentinel lymph node positivity of patients with ductal carcinoma in situ or microinvasive breast cancer. , 2006, American journal of surgery.

[22]  K. Malone,et al.  Risk of invasive breast carcinoma among women diagnosed with ductal carcinoma in situ and lobular carcinoma in situ, 1988‐2001 , 2006, Cancer.

[23]  S. Schnitt,et al.  Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer , 2006, Modern Pathology.

[24]  S. Joslyn.  Ductal Carcinoma in Situ: Trends in Geographic, Temporal, and Demographic Patterns of Care and Survival , 2006, The breast journal.

[25]  L. Solin,et al.  Long‐Term Outcome for Mammographically Detected Ductal Carcinoma In Situ Managed with Breast Conservation Treatment: Prognostic Significance of Reexcision , 2006, Cancer journal.

[26]  S. Swain,et al.  Ductal carcinoma in situ, complexities and challenges. , 2004, Journal of the National Cancer Institute.

[27]  M. Silverstein.  The University of Southern California/Van Nuys prognostic index for ductal carcinoma in situ of the breast. , 2003, American journal of surgery.

[28]  Ian O Ellis,et al.  The diagnosis and management of pre-invasive breast disease: Ductal carcinoma in situ (DCIS) and atypical ductal hyperplasia (ADH) – current definitions and classification , 2003, Breast Cancer Research.

[29]  S. Shousha,et al.  Oestrogen receptor negativity as a marker for high‐grade ductal carcinoma in situ of the breast , 2003, Histopathology.

[30]  G. Giles,et al.  Biological markers that predict clinical recurrence in ductal carcinoma in situ of the breast. , 2003, European journal of cancer.

[31]  A. Douglas-Jones,et al.  Effect of margins of excision on recurrence after local excision of ductal carcinoma in situ of the breast , 2002, Journal of clinical pathology.

[32]  C. Lemanski,et al.  Breast-conserving therapy for ductal carcinoma in situ of the breast: the French Cancer Centers' experience. , 2002, International journal of radiation oncology, biology, physics.

[33]  T. Lennard,et al.  Aggressive local treatment for screen-detected DCIS results in very low rates of recurrence. , 2001, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[34]  M. Fernö,et al.  Cell biological factors in ductal carcinoma in situ (DCIS) of the breast-relationship to ipsilateral local recurrence and histopathological characteristics. , 2001, European journal of cancer.

[35]  M. J. van de Vijver,et al.  Histological type and marker expression of the primary tumour compared with its local recurrence after breast-conserving therapy for ductal carcinoma in situ , 2001, British Journal of Cancer.

[36]  F. Vicini,et al.  Intraductal carcinoma of the breast: pathologic features associated with local recurrence in patients treated with breast-conserving therapy. , 2000, The American journal of surgical pathology.

[37]  J. Coindre,et al.  Application of the Van Nuys prognostic index in a retrospective series of 367 ductal carcinomas in situ of the breast examinated by serial macroscopic sectioning: Practical considerations , 2000, Breast Cancer Research and Treatment.

[38]  J. Gornbein,et al.  Outcomes and factors impacting local recurrence of ductal carcinoma in situ , 2000, Cancer.

[39]  C. Poremba,et al.  Comparative genomic hybridization of ductal carcinoma in situ of the breast—evidence of multiple genetic pathways , 1999, The Journal of pathology.

[40]  M. J. Silverstein,et al.  Prognostic classification of breast ductal carcinoma-in-situ , 1995, The Lancet.

[41]  W. McGuire,et al.  Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. , 1992, Human pathology.

[42]  C. Mariotti,et al.  Ductal Carcinoma in Situ of the Breast , 2018, Springer International Publishing.

[43]  A. Chagpar,et al.  Epidemiology of Ductal Carcinoma In Situ , 2015 .

[44]  J. Simpson.  Update on atypical epithelial hyperplasia and ductal carcinoma in situ. , 2009, Pathology.

[45]  Robert C. Frazier,et al.  Impact of young age on outcome in patients with ductal carcinoma-in-situ treated with breast-conserving therapy. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  H. Höfler,et al.  Extensive ductal carcinoma In situ with small foci of invasive ductal carcinoma: Evidence of genetic resemblance by CGH , 2000, International journal of cancer.

[47]  M. Silverstein,et al.  Outcomes and factors impacting local recurrence of ductal carcinoma in situ , 2000, Cancer.